Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Screener

Funds

Advisors

Advisor Access

News

What the Actavis Acquisition of Allergan Means for Mutual Fund Investors (AGN, ACT)

Shauna O'Brien Nov 17, 2014

On Monday morning, Actavis (ACT) reported that it has agreed to acquire Allergan (AGN) for approximately $66 billion in a cash and stock deal.

Inside the Deal

The $66 billion deal would create one of the top 10 global pharmaceutical companies by revenue. The deal comes after Allergan was faced with an unwanted takeover from Valeant in April, which was valued at $54 billion.

With this size, this acquisition would be one of the largest deals made in 2014.

Mutual Funds to Watch

Symbol	Mutual Fund	Exposure	Stake
VTSMX	Vanguard Total Stock Market Index	Allergan	1.69%
VFINX	Vanguard 500 Index	Allergan	1.04%
VGHCX	Vanguard Health Care	Actavis	3.23%
VTSMX	Vanguard Total Stock Market Index	Actavis	1.63%

The Bottom Line

This deal adds to the many major acquisitions that have already taken place in 2014 and is likely to be one of the biggest acquisitions this year. Major news events are very important for mutual fund investors to be aware of – even if the funds you own only have a small stake in the affected companies.